Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation
(HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral
blood stem cell transplant in adults and bone marrow stem cell transplant in children.
Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be
used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well
this treatment works in patients with hematologic malignancies.
Hematologic, Leukemia, Lymphoma, Myelodysplastic Syndrome
Phase II
Adults
Not Available
Not Available
Dholaria, Bhagirathbhai
National
Vanderbilt University
04-12-2022
Treatment
VICCCTT2171
NCT04904588

Eligibility

1 Years
BOTH
NO
Inclusion Criteria:

Age > 18 years and 66 years (chemotherapy-based conditioning) or 61 years (total body irradiation [TBI]-based conditioning) at the time of signing informed consent

Planned MAC regimen as defined per protocol

Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 35 years

Product planned for infusion is PBSC

HCT Comorbidity Index (HCT-CI) 5

One of the following diagnoses:

Acute myeloid leukemia (AML) acute lymphoblastic leukemia (ALL), or other acute leukemia in 1st remission or beyond with 5% marrow blasts and no circulating blasts or evidence of extra-medullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with myelodysplastic syndrome (MDS) with no circulating blasts and with 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with 5% or 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Cardiac function: Left ventricular ejection fraction > 45% based on most recent echocardiogram or multigated acquisition scan (MUGA) results

Estimated creatinine clearance > 60 mL/min calculated by equation

Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for hemoglobin > 50% and forced expiratory volume in first second (FEV1) predicted > 50% based on most recent pulmonary function test results

Liver function acceptable per local institutional guidelines

Karnofsky performance status (KPS) of > 70%

Subjects 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Stratum 2 Recipient Inclusion Criteria

Age > 18 years at the time of signing informed consent

Planned NMA/RIC regimen as defined per protocol

Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 35 years

Product planned for infusion is PBSC

One of the following diagnoses:

Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with 5% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with MDS with no circulating blasts and with 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with 5% or 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation

Patients with lymphoma with chemosensitive disease at the time of transplantation

Cardiac function: Left ventricular ejection fraction > 45% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure

Estimated creatinine clearance > 60 mL/min calculated by equation

Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted > 50% based on most recent pulmonary function test results

Liver function acceptable per local institutional guidelines

KPS of > 60%

Subjects 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Stratum 3 Recipient Inclusion Criteria

Age > 1 years and 21 years at the time of signing informed consent

Partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age 35 years

Product planned for infusion is BM

Planned MAC regimen as defined per protocol

One of the following diagnosis:

AML in 1st remission or beyond with 5% marrow blasts, no circulating blasts or evidence of extra-medullary disease. Pre-transplant MRD testing will be performed as per standard of practice at the treating institution. Patients with any MRD status are eligible and should be enrolled at the discretion of provider. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Patients MDS with no circulating blasts and less than 10% blasts in the bone marrow. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

ALL in 1st remission or beyond with 5% marrow blasts, no circulating blasts, or evidence of extra-medullary disease. Pre-transplant MRD testing will be performed as standard practice at the treating institution with the goal of achieving MRD of 0.01%. Patients with any MRD status are eligible and should be enrolled at the discretion of provider. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Other leukemia (mixed-phenotype acute leukemia [MPAL], CML, or other leukemia) in morphologic remission with 5% marrow blasts and no circulating blasts or evidence of extramedullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

Chemotherapy sensitive lymphoma in at least partial remission (PR)

KPS or Lansky performance score 70%

Cardiac function: Left ventricular ejection fraction of 50% and shortening fraction of 27% based on most recent echocardiogram

Glomerular Filtration Rate (GFR) of 60ml/min/1.73m2 measured by nuclear medicine scan or calculated from a 24 hour urine collection

Pulmonary function: DLCO corrected for hemoglobin, FEV1, and Forced Vital Capacity (FVC) of 50% if able to perform pulmonary function tests. If unable to perform pulmonary function tests, must have a resting pulse oximetry of >92% without supplemental oxygen.

Hepatic: Total bilirubin 2.5 mg/dL and alanine aminotransferase (ALT), aspartate aminotransferase (AST) 3x the upper limit of normal

Legal guardian permission must be obtained for subjects 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.

Subjects 18 years of age or legally authorized representative must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Donor Inclusion Criteria:

Must be unrelated to the subject and high-resolution HLA-matched at 4/8, 5/8, 6/8, or 7/8 (HLA-A, -B, -C, and -DRB1)

Donor must be typed at high-resolution for a minimum of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1

Age > 18 years and 35 years at the time of signing informed consent

Meet the donor registries' medical suitability requirements for PBSC or BM donation

Must undergo eligibility screening according to current Food and Drug Administration (FDA) requirements. Donors who do not meet one or more of the donor screening requirements may donate under urgent medical need.

Must agree to donate PBSC (or BM for stratum 3)

Must have the ability to give standard (non-study) informed consent according to applicable donor regulatory requirements Recipient Exclusion Criteria (Strata 1, 2 and 3):

Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available

Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing

Primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia, polycythemia vera, or MDS with grade 4 marrow fibrosis

Subjects with a prior allogeneic HSC transplant

Subjects with an autologous HSC transplant within the past 3 months

Females who are breast-feeding or pregnant

Uncontrolled bacterial, viral or fungal infection at the time of the transplant preparative regimen

Concurrent enrollment on other interventional GVHD clinical trial (enrollment on supportive care trials may be allowed after discussion with Principal Investigators)

Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant.

Patients who are HIV+ with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.



Exclusion Criteria:

Donor unwilling or unable to donate

Recipient positive anti-donor HLA antibodies against a mismatched HLA in the selected donor determined by the presence of donor specific HLA antibodies (DSA) to any mismatched HLA allele/antigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, -DQB1, -DPA1, -DPB1) with median fluorescence intensity (MFI) >3000 by microarray-based single antigen bead testing. In patients receiving red blood cell or platelet transfusions, DSA evaluation must be performed or repeated post-transfusion and prior to donor mobilization and initiation of recipient preparative regimen.

To learn more about any of our clinical
trials, call 615-936-8422.